- Home
- DH vs CDXC Comparison
DH vs CDXC Comparison
Compare DH & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DH
- CDXC
- Stock Information
- Founded
- DH 2011
- CDXC 1999
- Country
- DH United States
- CDXC United States
- Employees
- DH N/A
- CDXC N/A
- Industry
- DH Computer Software: Prepackaged Software
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- DH Technology
- CDXC Health Care
- Exchange
- DH Nasdaq
- CDXC Nasdaq
- Market Cap
- DH 494.3M
- CDXC 546.9M
- IPO Year
- DH 2021
- CDXC N/A
- Fundamental
- Price
- DH $4.25
- CDXC $7.63
- Analyst Decision
- DH Hold
- CDXC Strong Buy
- Analyst Count
- DH 10
- CDXC 2
- Target Price
- DH $6.28
- CDXC $8.00
- AVG Volume (30 Days)
- DH 431.6K
- CDXC 3.0M
- Earning Date
- DH 11-07-2024
- CDXC 10-31-2024
- Dividend Yield
- DH N/A
- CDXC N/A
- EPS Growth
- DH N/A
- CDXC N/A
- EPS
- DH N/A
- CDXC 0.02
- Revenue
- DH $255,846,000.00
- CDXC $91,668,000.00
- Revenue This Year
- DH $2.14
- CDXC $18.64
- Revenue Next Year
- DH $1.77
- CDXC $20.72
- P/E Ratio
- DH N/A
- CDXC $388.80
- Revenue Growth
- DH 3.97
- CDXC 9.95
- 52 Week Low
- DH $3.19
- CDXC $1.32
- 52 Week High
- DH $10.62
- CDXC $7.85
- Technical
- Relative Strength Index (RSI)
- DH 48.23
- CDXC 75.32
- Support Level
- DH $4.05
- CDXC $6.80
- Resistance Level
- DH $4.77
- CDXC $7.67
- Average True Range (ATR)
- DH 0.25
- CDXC 0.58
- MACD
- DH -0.01
- CDXC 0.07
- Stochastic Oscillator
- DH 28.97
- CDXC 91.16
About DH Definitive Healthcare Corp.
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. The company's solutions provide accurate and comprehensive information on healthcare providers and their activities to help customers optimize everything from product development to go-to-market planning and sales and marketing execution. Geographically, it derives a majority of its revenue from the United States.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.